Stockscreener 앱 받기
3.95
2.73%
0.105
시간 외 거래:
3.97
0.02
+0.51%
전일 마감가:
$3.845
열려 있는:
$3.78
하루 거래량:
3.73M
Relative Volume:
3.58
시가총액:
$278.83M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-1.386
EPS:
-2.85
순현금흐름:
$-108.55M
1주 성능:
-9.82%
1개월 성능:
-2.47%
6개월 성능:
-2.47%
1년 성능:
-9.20%
1일 변동 폭
$3.72
$3.98
1주일 범위
$3.61
$4.53
52주 변동 폭
$3.61
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.95 | 278.83M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wells Fargo Upgrades C4 Therapeutics (CCCC) - MSN
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics (NASDAQ:CCCC) Upgraded at Wells Fargo & Company - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
C4 Therapeutics stock hits 52-week low at $3.77 - Investing.com
Fmr LLC Buys 162,314 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Point72 Asset Management L.P. Raises Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Unveils Promising Phase 1 Data: Strong Response Rates in Multiple Myeloma & Lymphoma Trial - StockTitan
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - The Manila Times
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Akebia Therapeutics Awards 121,000 Stock Options to New Employees in Retention Push - StockTitan
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wasatch Advisors LP Purchases 830,218 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):